The Pharmome Map: a comprehensive public dataset for drug-target interaction modeling A Blog post by Hugging Science on Hugging Face

Generating open pharmacology datasets is what we do! Check out our existing work: huggingface.co/blog/hugging...

EvE Bio partners with OpenAI Foundation on "AI for Alzheimer's" : EvE Bio EvE Bio is partnering with the OpenAI Foundation. Can AI help us design drugs for Alzheimer's? Not without the right data. EvE generates it.

EvE Bio is partnering with The OpenAI Foundation on their AI for Alzheimer's initiative!

Allosteric modulators hold promise as Alzheimer's drugs, but designing them is hard. AI models could help...if they had the right data. That's where we come in.
evebio.org/eve-bio-part...

What would you like to see us include?

6) Compounds in widespread human use, even if not FDA approved

5) Drug metabolites

4) Drugs currently in later stage clinical trials

3) Failed clinical candidates

2) Scheduled approved drugs (controlled substances)

1) Recently approved drugs not in our first compound library

We're busy here at EvE Bio generating drug-target interaction data for GPCR, NR, and kinase targets. Meanwhile, we're expanding our compounds and we want your input! Our current library has 1,300 approved small molecule and peptide drugs. The next will include 6 categories: 🧵

DrugBank Online EvE Bio is now integrated into DrugBank, creating the largest public resource of drug–protein interactions and making off-target biology searchable, connected, and actionable for the first time.

Academic users of DrugBank can also check our integration there: go.drugbank.com/evebio

Eve Bio: Pharmome Data Explore/download data for 1,400 FDA drugs' actions on an ever-growing collection of gene products.

Download data files by filling out the form here 🔗 data.evebio.org Multiple versions are available depending on your use case, from viewing summary results in a spreadsheet to building ML models.

eve-bio/drug-target-activity · Datasets at Hugging Face We’re on a journey to advance and democratize artificial intelligence through open source and open science.

For programmatic access, find us on @hf.co : huggingface.co/datasets/eve...

For interactive exploration, go directly to tinyurl.com/eve-results

New data is live!! With 25 new kinases, we have a total of 420,497 drug-target interaction results! There are multiple ways to access the dataset 🧵

Eve Bio: Pharmome Data Explore/download data for 1,400 FDA drugs' actions on an ever-growing collection of gene products.

To be sure you know about each new data release, subscribe to our "latest news" email list at 🔗 data.evebio.org

Eve Bio: Pharmome Data Explore/download data for 1,400 FDA drugs' actions on an ever-growing collection of gene products.

The 25 new kinases added tomorrow will bring EvE's dataset to 67 total kinases, in addition to 85 7-transmembrane receptors and 32 nuclear receptors. All of these have activity measurements (or confirmed inactivity) for our 1,400 compound small molecule drug library.

It's the final day of our data release preview -- data will be posted tomorrow!

The last five new targets to preview are metabolic and regulatory kinases: YES, FER, FES, PASK1, and CCK2

We'll finish up the preview tomorrow!

These less-characterized kinases represent the expanding frontier of cancer target space. Meanwhile, our previous release already includes well-established oncology targets like EGFR, BTK, and Aurora kinases -- along with EGFR and BTK mutants. Explore those results: 🔗 data.evebio.org

Day 5 of our kinase preview for our imminent data release: Emerging Oncology Targets

We're adding four kinases gaining traction in cancer drug discovery: PVK2, SVK, TBK1, and CGK2.

These kinases help cells decide their fate under stress - whether to survive, adapt, or undergo apoptosis. Understanding how drugs modulate these stress-response kinases is crucial for cancer therapy, where the goal is often to tip stressed tumor cells toward death rather than survival.

It's data release week at EvE! Continuing with day 4 of our preview of the 25 kinases we'll release later this week, today's focus is on stress and survival pathways.

We're adding four kinases involved in cellular stress responses: MST2, MSK1, DAPK1, and ROS.

...or go directly to our methods page: tinyurl.com/eve-methods

As we release data at EvE, we also provide methods details about our assays, our quantitative screening and profiling approach, and our data processing. Access this in our interactive data explorer, download a pdf or use our chatbot on our download site...

These kinases translate calcium spikes into cellular decisions. CaMK2 plays important roles in cardiac function and neuronal signaling, while CaMKK2 has emerged as a metabolic drug target, with inhibitors explored for obesity and diabetes.

For the day 3 preview of EvE's kinase data release, the theme is calcium.

We're adding three "calcium decoders" to our dataset: CaMK2a, CaMKK2, and MLK1.

If you'd like to explore our released data, in addition to downloads and programmatic access, we have an interactive data exploration app. Follow the Explore Data link here: 🔗 data.evebio.org

Day 2 preview of EvE's kinase data release: The RSK Family

We're adding 5 ribosomal S6 kinases to our dataset: RSK1, RSK2, RSK3, RSK4, and p70S6K.

These kinases are key effectors of the MAPK signaling pathway, and are important targets in cancer research.

You can also access our data on Hugging Face 🔗 huggingface.co/datasets/eve...